Sleep Disorders |

An Open Label Pilot Study to Determine the Efficacy of Ramelteon in REM Sleep Behavior Disorder (RBD) FREE TO VIEW

Roopika Reddy, MD; Daniel Rifkin, MD
Author and Funding Information

Department of Sleep Medicine at State University of New York at Buffalo, Buffalo, NY

Chest. 2013;144(4_MeetingAbstracts):990A. doi:10.1378/chest.1703579
Text Size: A A A
Published online


SESSION TITLE: Sleep Disorders II

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Wednesday, October 30, 2013 at 02:45 PM - 04:15 PM

PURPOSE: Different drug treatments including clonazepam, dopamine agonists and melatonin are used for the treatment of REM sleep behavior disorder. We hypothesize that ramelteon by mimicking the action of endogenous melatonin, will produce significant improvement of both clinical as well as polysomnographic features of RBD.

METHODS: This is a retrospective chart review and descriptive study of patients with REM sleep behavior disorder who were treated with ramelteon. Ten patients with clinical as well as polysomnographic RBD were included in the study. Patients were treated with Ramelteon 8mg orally at night for at least 4 weeks.

RESULTS: Ramelteon was shown to have very good results with greater than 50% reduction in frequency and severity of RBD symptoms in 60% of patients. Ramelteon was not effective in three patients and one patient was not compliant with the treatment.

CONCLUSIONS: Ramelteon appears to produce significant improvement of both clinical as well as polysomnographic features of RBD. If the effect of ramelteon in RBD is similar to that of melatonin, it may extend beyond the end of treatment at least for several weeks and would be less likely to cause relapse after missing a single dose or lead to untoward effects as seen with the long-term use of clonazepam.

CLINICAL IMPLICATIONS: Ramelteon seems promising as the drug of choice for RBD but further randomized controlled trials are needed to evaluate its efficacy.

DISCLOSURE: Daniel Rifkin: Grant monies (from industry related sources): Dr. Rifkin has received a research support from Takeda pharmaceuticals The following authors have nothing to disclose: Roopika Reddy

The use of Ramelteon for RBD is considered research as it is not yet approved for the treatment of RBD.




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543